The Korean Journal of Medicine

  • 제84권1호
  • /
  • Pages.13-18
  • /
  • 2013
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

일차성 사구체신염의 치료

Treatment of Primary Glomerulonephritis

  • 임천규 (경희대학교 의과대학 내과학교실)
  • Ihm, Chun-Gyoo (Department of Internal Medicine, Kyung Hee University College of Medicine)
  • 발행 : 2013.01.01
⟨ 이전 논문 다음 논문 ⟩

초록

Much progress has been made in the elucidation of potential pathogenetic mechanisms of glomerulonephritis such as anti-PLA2R autoantibody in membranous nephropathy and under-galactosylated IgA1 in IgA nephropathy as well as in the fields of treatment. This knowledge is, hopefully in the future, being applied in the development of the creation of rational therapeutic approaches. Current treatment strategies for glomerular diseases recommended by many clinical studies include high-dose glucocorticoids, calcineurin inhibitors, cyclophosphamide, mycophenolate mofetil, and rituximab. Although these therapies have been effective in treating immune-mediated glomerular diseases, they all have potentially serious side effects.

키워드

참고문헌

  1. Liu LL, Qin Y, Cai JF, et al. Th17/Treg imbalance in adult patients with minimal change nephrotic syndrome. Clin Immunol 2011;139:314-320. https://doi.org/10.1016/j.clim.2011.02.018
  2. Garin EH, Mu W, Arthur JM, et al. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int 2010;78:296-302. https://doi.org/10.1038/ki.2010.143
  3. Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008; 14:931-938. https://doi.org/10.1038/nm.1857
  4. Waldman M, Crew RJ, Valeri A, et al. Adult minimalchange disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2007;2:445-453. https://doi.org/10.2215/CJN.03531006
  5. Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. N Engl J Med 1982;306:451-454. https://doi.org/10.1056/NEJM198202253060803
  6. Eguchi A, Takei T, Yoshida T, Tsuchiya K, Nitta K. Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome. Nephrol Dial Transplant 2010;25:124-129. https://doi.org/10.1093/ndt/gfp422
  7. Stirling CM, Mathieson P, Boulton-Jones JM, et al. Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units. QJM 2005;98:443-449. https://doi.org/10.1093/qjmed/hci072
  8. Cattran DC, Appel GB, Hebert LA, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis: North America Nephrotic Syndrome Study Group. Kidney Int 1999;56:2220-2226. https://doi.org/10.1046/j.1523-1755.1999.00778.x
  9. Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361:11-21. https://doi.org/10.1056/NEJMoa0810457
  10. Beck LH Jr, Fervenza FC, Beck DM, et al. Rituximabinduced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011;22:1543-1550. https://doi.org/10.1681/ASN.2010111125
  11. Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995;48:1600-1604. https://doi.org/10.1038/ki.1995.453
  12. Cattran DC, Appel GB, Hebert LA, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001;59:1484-1490. https://doi.org/10.1046/j.1523-1755.2001.0590041484.x
  13. Fervenza FC, Abraham RS, Erickson SB, et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 2010;5:2188-2198. https://doi.org/10.2215/CJN.05080610
  14. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol 2011;31:341-348. https://doi.org/10.1016/j.semnephrol.2011.06.005
  15. Mestecky J, Tomana M, Crowley-Nowick PA, Moldoveanu Z, Julian BA, Jackson S. Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy. Contrib Nephrol 1993;104:172-182.
  16. Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004;15:157-163. https://doi.org/10.1097/01.ASN.0000103869.08096.4F
  17. Lv J, Zhang H, Chen Y, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 2009;53:26-32. https://doi.org/10.1053/j.ajkd.2008.07.029
  18. Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 2009;24:3694-3701. https://doi.org/10.1093/ndt/gfp356
  19. Choi S, Lee D, Jeong KH, et al. Prognostic relevance of clinical and histological features in IgA nephropathy treated with steroid and angiotensin receptor blockers. Clin Nephrol 2009;72:353-359. https://doi.org/10.5414/CNP72353
  20. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002;13:142-148.
  21. Shin JI, Lim BJ, Kim PK, Lee JS, Jeong HJ, Kim JH. Effects of cyclosporin A therapy combined with steroids and angiotensin converting enzyme inhibitors on childhood IgA nephropathy. J Korean Med Sci 2010;25:723-727. https://doi.org/10.3346/jkms.2010.25.5.723
  22. Tumlin JA, Hennigar RA. Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy. Semin Nephrol 2004;24:256-268. https://doi.org/10.1016/j.semnephrol.2004.01.006
  23. Cui Z, Zhao J, Jia XY, et al. Anti-glomerular basement membrane disease: outcomes of different therapeutic regimens in a large single-center Chinese cohort study. Medicine (Baltimore) 2011;90:303-311. https://doi.org/10.1097/MD.0b013e31822f6f68
  24. Lockwood CM, Rees AJ, Pearson TA, Evans DJ, Peters DK, Wilson CB. Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome. Lancet 1976;1:711-715.

피인용 문헌

  1. 음곡에 시술한 석위약침이 Lipopolysaccharide로 유도된 흰쥐의 신장염에 미치는 영향 vol.32, pp.3, 2013, https://doi.org/10.13045/acupunct.2015035